FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique
This article was originally published in The Tan Sheet
Executive Summary
Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug
You may also be interested in...
Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?
J&J/Merck is still pursuing an Rx-to-OTC switch of a 20 mg dose of the cholesterol-lowering therapy Mevacor (lovastatin), according to VP-Global Regulatory & Scientific Affairs Edwin Hemwall, PhD
Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?
J&J/Merck is still pursuing an Rx-to-OTC switch of a 20 mg dose of the cholesterol-lowering therapy Mevacor (lovastatin), according to VP-Global Regulatory & Scientific Affairs Edwin Hemwall, PhD
Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?
J&J/Merck is still pursuing an Rx-to-OTC switch of a 20 mg dose of the cholesterol-lowering therapy Mevacor (lovastatin), according to VP-Global Regulatory & Scientific Affairs Edwin Hemwall, PhD